ReviewNature reviews. Clinical oncology2012
What are we learning from the cancer genome?
Review in Nature reviews. Clinical oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Smart Multifunctional Nanoparticles in Cancer Theranostics: Progress and Prospect.Pharmaceutical nanotechnology · 2025Review
- Biomimetic Hydrogel Strategies for Cancer Therapy.Gels (Basel, Switzerland) · 2024Review
- TRIPODD: a Novel Fluorescence Imaging Platform for In Situ Quantification of Drug Distribution and Therapeutic Response.Molecular imaging and biology · 2021Article
- In vivo modeling of metastatic human high-grade serous ovarian cancer in mice.PLoS genetics · 2020Article
- Fluorescent Imaging forProceedings of SPIE--the International Society for Optical Engineering · 2020Article
- Review
- Developments in Point-of-Care Diagnostic Technology for Cancer Detection.Diagnostics (Basel, Switzerland) · 2018Review
- Acquired somaticOncotarget · 2017Article
- Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis.Oncotarget · 2016Article
- Cancer Cell Fusion: Mechanisms Slowly Unravel.International journal of molecular sciences · 2016Review
- NRAS germline variant G138R and multiple rare somatic mutations on APC in colorectal cancer patients in Taiwan by next generation sequencing.Oncotarget · 2016Article
- Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer.Cancer · 2016Article
- Toward precision medicine in neurological diseases.Annals of translational medicine · 2016Review
- A roadmap for precision medicine in the epilepsies.The Lancet. Neurology · 2015Review
- Homologous Mutation to Human BRAF V600E Is Common in Naturally Occurring Canine Bladder Cancer--Evidence for a Relevant Model System and Urine-Based Diagnostic Test.Molecular cancer research : MCR · 2015Article
- The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor.Cell reports · 2014Article
- Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail.British journal of cancer · 2014Article
- An improved understanding of cancer genomics through massively parallel sequencing.Translational cancer research · 2014Article
- One hundred years of somatic mutation theory of carcinogenesis: is it time to switch?BioEssays : news and reviews in molecular, cellular and developmental biology · 2014Article
- Clinicians' expectations for gene-driven cancer therapy.Clinical Medicine Insights. Oncology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Massively parallel approaches to nucleic acid sequencing have matured from proof-of-concept to commercial products during the past 5 years. These technologies are now widely accessible, increasingly affordable, and have already exerted a transformative influence on the study of human cancer. Here, we review new features of cancer genomes that are being revealed by large-scale applications of these technologies. We focus on those insights most likely to affect future clinical practice. Foremost among these lessons, we summarize the formidable genetic heterogeneity within given cancer types that is appreciable with higher resolution profiling and larger sample sets. We discuss the inherent challenges of defining driving genomic events in a given cancer genome amidst thousands of other somatic events. Finally, we explore the organizational, regulatory and societal challenges impeding precision cancer medicine based on genomic profiling from assuming its place as standard-of-care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.